RevOpsis Therapeutics has entered a strategic manufacturing collaboration with contract development and manufacturing organisation Kemwell Biopharma to accelerate the development of new multispecific biologics.
Kemwell will concurrently produce RO-104, an asset that can bind three validated targets implicated with nAMD.
The alliance will harness the manufacturing prowess of Kemwell alongside RevOpsis’ Rev-Mod platform, to streamline the development process for multispecific biologics.
RevOpsis will gain access to a biologics development solution, enabling a swift transition from pre-clinical works to first-in-human clinical trials to advance the development of RO-104 and the broader platform.
Merging the plug-and-play multispecific biologics platform of RevOpsis with the deep biologics development and manufacturing expertise of Kemwell will aid the partnership to quicken the discovery of therapeutics and advance them to investigational new drug (IND) submission.
The partnership is designed to link preclinical works, process development and clinical production to lower the complexity and timelines typically associated with handling early Good Manufacturing Practices (GMP) processes.
RevOpsis co-founder and interim CEO Ram Bhandari said: “Partnering with Kemwell is a pivotal step in accelerating the development of our lead candidate, RO-104, and advancing our pipeline of innovative multispecific biologics.
“Kemwell’s exemplary track record in high-quality biologics manufacturing and their efficiency in reducing timelines, combined with our proprietary Rev-Mod platform, ensures we can deliver transformative therapies to patients efficiently. This collaboration aligns with our mission to develop groundbreaking treatments expeditiously, and bring our innovation to patients worldwide.”
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.